This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-38 (Canceled).

39. (Currently amended) A process of forming ribavirin particles, the process comprising:

mixing ribavirin with ~~an~~ at least one excipient to form a uniform mixture;

forming the uniform mixture into a granulated mass by adding water to the mixture in the range of 15-79% of the total mixture; and

shaping the ~~mixture~~ granulated mass into ribavirin particles.

40. (Previously presented) The process according to claim 39, further comprising filling a capsule with the particles resulting in a total weight ranging from 243 mg to 297 mg of particles in the capsule.

41. (Previously presented) The process according to claim 40, further comprising adding a lubricant to the particles before filling the capsule.

42. (Currently amended) The process according to claim 41, wherein the at least one excipient is povidone.

43. (Currently amended) The process according to claim 39, wherein the at least one excipient is selected from the group consisting of a binder, a filler, and a disintegrant.

44. (Previously presented) The process according to claim 43, wherein the binder, filler, and disintegrant are selected from the group consisting of: povidone, starch, lactose, polyethylene glycol, hydroxypropyl methylcellulose, croscarmellose sodium, cellulose, bentonite, cross-povidones, microcrystalline cellulose, and sucrose.

45. (Previously presented) The process according to claim 39, wherein the shaping step is accomplished by spheronization.

46. (Previously presented) The process according to claim 39, further comprising heating the mixture to a temperature ranging from about 35 °C to about 45 °C, until the mixture contains a moisture content ranging from 0.5% to 5.0%.

47. (Currently Amended) A process of forming a ribavirin mixture, the process comprising:

forming a mixture comprising ~~about 35% to about 80% of ribavirin by weight, and a binder~~ ribavirin, microcrystalline cellulose and povidone;

adding water to the mixture to form a granulated mass; and

drying the granulated mass.

48. (Previously presented) The process according to claim 47, further comprising shaping the granulated mass into particles.

49. (Currently amended) A process of forming a ribavirin mixture, the process comprising:

combining ribavirin with ~~an~~ at least one excipient to form a mixture;

adding water to the mixture to form a granulated mass; and

drying the granulated mass.

50. (Previously presented) The process according to claim 49, wherein water is added to the mixture in the range of 15-79% of the total mixture.

51. (Previously presented) A process of forming a ribavirin mixture, the process comprising:

combining ribavirin with a binder, disintegrant and wetting agent to form a granulated mixture; and

drying the granulated mixture, wherein the wetting agent is water.

52. (Previously presented) The process according to claim 51, wherein water is added in the range of 15-79% of the total mixture.

53. (Previously presented) The process according to claim 51, further comprising shaping the granulated mixture into particles and preparing a pharmaceutical dosage with the particles.

Claims 54-58. (Canceled)

59. (New) A process of forming ribavirin particles, the process comprising:

combining ribavirin with at least microcrystalline cellulose, povidone and cross-povidone to form a mixture;

adding water to the mixture to form a wet granulated mass; and

shaping the wet granulated mass into ribavirin particles.

60. (New) The process according to claim 59, further comprising preparing a pharmaceutical dosage with the ribavirin particles.

61. (New) The process according to claim 59, further comprising adding a lubricant to the ribavirin particles.

62. (New) The process according to claim 59, further comprising filling a capsule with the ribavirin particles.

63. (New) The process according to claim 60, wherein the pharmaceutical dosage is a capsule.